As soon as Phase 3 results were published, Israel added the new combo-therapy of venetoclax and azacytidine from global biotech AbbVie to the basket of treatments for acute myeloid leukemia (AML). Israel had the most patients enrolled in the Phase … Continue reading →

I reported previously (10th Jun) results of trials of one pancreatic treatment at Israel’s Sheba hospital. Sheba are now starting Phase 3 trials of another, CPI-613 (devimistat) from Israeli biotech Rafael, which can also treat Acute Myeloid Leukemia and other … Continue reading →

Ezer Mizion’s data processor found she was a DNA match on the Israeli NGO’s bone marrow registry for a woman suffering from Acute Myeloid Leukemia (AML). She flew halfway around the world to donate some of her stem cells. She … Continue reading →

The US FDA has just approved the home administration of Teva’s Synribo (omacetaxine mepesuccinate). Physicians who treat adults with chronic or accelerated phase Chronic Myeloid Leukemia (CML) can now administer Synribo therapy in the patient’s own home. http://www.globes.co.il/en/article-teva-receives-fda-approval-for-leukemia-treatment-1000936451